Reply to: Graefe-Mody U, Friedrich C, Port A et al. Effect of renal impairment on the pharmacokinetics of the dipeptidyl peptidase-4 inhibitor linagliptin: Graefe-Mody U, Friedrich C, Port A et al. Effect of renal impairment on the pharmacokinetics of the dipeptidyl peptidase-4 inhibitor linagliptin. Diabetes Obes Metab 2011; 13: 939-946

Ben Snyder; Thomas Polasek; Matthew Doogue

doi:10.1111/j.1463-1326.2012.01588.x

Reply to: Graefe-Mody U, Friedrich C, Port A et al. Effect of renal impairment on the pharmacokinetics of the dipeptidyl peptidase-4 inhibitor linagliptin: Graefe-Mody U, Friedrich C, Port A et al. Effect of renal impairment on the pharmacokinetics of the dipeptidyl peptidase-4 inhibitor linagliptin. Diabetes Obes Metab 2011; 13: 939-946

Ben Snyder, Thomas Polasek, Matthew Doogue

Research output: Contribution to journal › Letter › peer-review

Original language	English
Pages (from-to)	670
Number of pages	1
Journal	Diabetes, Obesity and Metabolism
Volume	14
Issue number	7
DOIs	https://doi.org/10.1111/j.1463-1326.2012.01588.x
Publication status	Published - Jul 2012

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1111/j.1463-1326.2012.01588.x

Cite this

Snyder, B., Polasek, T., & Doogue, M. (2012). Reply to: Graefe-Mody U, Friedrich C, Port A et al. Effect of renal impairment on the pharmacokinetics of the dipeptidyl peptidase-4 inhibitor linagliptin: Graefe-Mody U, Friedrich C, Port A et al. Effect of renal impairment on the pharmacokinetics of the dipeptidyl peptidase-4 inhibitor linagliptin. Diabetes Obes Metab 2011; 13: 939-946. Diabetes, Obesity and Metabolism, 14(7), 670. https://doi.org/10.1111/j.1463-1326.2012.01588.x

Snyder, Ben ; Polasek, Thomas ; Doogue, Matthew. / Reply to: Graefe-Mody U, Friedrich C, Port A et al. Effect of renal impairment on the pharmacokinetics of the dipeptidyl peptidase-4 inhibitor linagliptin : Graefe-Mody U, Friedrich C, Port A et al. Effect of renal impairment on the pharmacokinetics of the dipeptidyl peptidase-4 inhibitor linagliptin. Diabetes Obes Metab 2011; 13: 939-946. In: Diabetes, Obesity and Metabolism. 2012 ; Vol. 14, No. 7. pp. 670.

@article{b7f7299db72a47f3a54ba609531760f8,

title = "Reply to: Graefe-Mody U, Friedrich C, Port A et al. Effect of renal impairment on the pharmacokinetics of the dipeptidyl peptidase-4 inhibitor linagliptin: Graefe-Mody U, Friedrich C, Port A et al. Effect of renal impairment on the pharmacokinetics of the dipeptidyl peptidase-4 inhibitor linagliptin. Diabetes Obes Metab 2011; 13: 939-946",

author = "Ben Snyder and Thomas Polasek and Matthew Doogue",

year = "2012",

month = jul,

doi = "10.1111/j.1463-1326.2012.01588.x",

language = "English",

volume = "14",

pages = "670",

journal = "Diabetes, Obesity and Metabolism",

issn = "1462-8902",

publisher = "BLACKWELL SYNERGY",

number = "7",

}

Snyder, B, Polasek, T & Doogue, M 2012, 'Reply to: Graefe-Mody U, Friedrich C, Port A et al. Effect of renal impairment on the pharmacokinetics of the dipeptidyl peptidase-4 inhibitor linagliptin: Graefe-Mody U, Friedrich C, Port A et al. Effect of renal impairment on the pharmacokinetics of the dipeptidyl peptidase-4 inhibitor linagliptin. Diabetes Obes Metab 2011; 13: 939-946', Diabetes, Obesity and Metabolism, vol. 14, no. 7, pp. 670. https://doi.org/10.1111/j.1463-1326.2012.01588.x

Reply to: Graefe-Mody U, Friedrich C, Port A et al. Effect of renal impairment on the pharmacokinetics of the dipeptidyl peptidase-4 inhibitor linagliptin: Graefe-Mody U, Friedrich C, Port A et al. Effect of renal impairment on the pharmacokinetics of the dipeptidyl peptidase-4 inhibitor linagliptin. Diabetes Obes Metab 2011; 13: 939-946. / Snyder, Ben; Polasek, Thomas; Doogue, Matthew.
In: Diabetes, Obesity and Metabolism, Vol. 14, No. 7, 07.2012, p. 670.

Research output: Contribution to journal › Letter › peer-review

TY - JOUR

T1 - Reply to: Graefe-Mody U, Friedrich C, Port A et al. Effect of renal impairment on the pharmacokinetics of the dipeptidyl peptidase-4 inhibitor linagliptin

T2 - Graefe-Mody U, Friedrich C, Port A et al. Effect of renal impairment on the pharmacokinetics of the dipeptidyl peptidase-4 inhibitor linagliptin. Diabetes Obes Metab 2011; 13: 939-946

AU - Snyder, Ben

AU - Polasek, Thomas

AU - Doogue, Matthew

PY - 2012/7

Y1 - 2012/7

UR - https://dom-pubs.onlinelibrary.wiley.com/doi/pdf/10.1111/j.1463-1326.2012.01588.x

UR - http://www.scopus.com/inward/record.url?scp=84861880996&partnerID=8YFLogxK

U2 - 10.1111/j.1463-1326.2012.01588.x

DO - 10.1111/j.1463-1326.2012.01588.x

M3 - Letter

SN - 1462-8902

VL - 14

SP - 670

JO - Diabetes, Obesity and Metabolism

JF - Diabetes, Obesity and Metabolism

IS - 7

ER -

Snyder B, Polasek T, Doogue M. Reply to: Graefe-Mody U, Friedrich C, Port A et al. Effect of renal impairment on the pharmacokinetics of the dipeptidyl peptidase-4 inhibitor linagliptin: Graefe-Mody U, Friedrich C, Port A et al. Effect of renal impairment on the pharmacokinetics of the dipeptidyl peptidase-4 inhibitor linagliptin. Diabetes Obes Metab 2011; 13: 939-946. Diabetes, Obesity and Metabolism. 2012 Jul;14(7):670. doi: 10.1111/j.1463-1326.2012.01588.x

UN SDGs

Access to Document

Other files and links

Cite this